A global rare disease specialty pharmaceutical company sought to evaluate the attractiveness of different physician specialty targets.
CRA approach
- Conducted an extensive literature review on the rare disease to understand its natural history and collect reported prevalence of its typical clinical features
- Conducted primary research with KOLs and specialty physicians to validate and detail understanding of natural history and referral patterns
- Created a prevalence-based model systematically evaluating attractiveness of lead symptomatologies (single clinical features or combinations thereof) along eight-dimensional attractiveness grid
Client impact
- Identified primary and secondary specialty targets, taking into account main competitor’s actions
- Created transparency on most current scientific literature and medical details of all lead symptomatologies and identified knowledge gaps
- Quantified patient opportunity by lead symptomatology and specialty based on this study and studies conducted in parallel
- Derived hypotheses on how to approach physicians to support patient finding
